Skip to main content
Have a personal or library account? Click to login
Serum tumor markers for screening and early diagnosis of ovarian cancer Cover

Serum tumor markers for screening and early diagnosis of ovarian cancer

Open Access
|Dec 2013

References

  1. 1. Guenther J, Stiles A, Champion JD The lived experience of ovarian cancer: a phenomenological approach. J Am Acad Nurse Pract. 2012; 24(10): 595-603.
  2. 2. Gentry-Maharaj A, Menon U Screening for ovarian cancer in the general population. Best Practice & Research Clinical Obstetrics & Gynaecology. 2012; 26: 243-256.
  3. 3. Zhang B, Cai FF, Zhong XY An overview of biomarkers for the ovarian cancer diagnosis. European Journal of Obstetrics and Gynecology. 2011; 158(2): 119-123.
  4. 4. Zang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W et al. Proteomics and Biomarkers for Ovarian Cancer Diagnosis, Annals of Clinical & Laboratory Science. 2010; 40(3): 218-225.
  5. 5. O'Malley D, Azodi M, Makkenchery A, Tangir J, McAlpine J, Kelly M. Serum protein markers for early detection on ovarian cancer. PNAS 2005; 102: 7677-82.
  6. 6. Jacobs IJ, Skates SJ, MacDonald N, Menon V, Rosenthal AN, Davies AP et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999; 353: 1207-1210.
  7. 7. Moore R G, Maclaughlan S Current clinical use of biomarkers for ovarian cancer. Current opinion in oncology. 09/2010; 22(5):492-7.
  8. 8. Lu KH, Skates S, Bevers TB, Newland W, Moore RG, Leeds L et al. A prospective US ovarian cancer screening study using the risk of ovarian cancer algorithm (ROCA). J Clin Oncol. 2010; 28:[suppl; abstract 5003]
  9. 9. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology. 2009;112: 40-46.
  10. 10. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T et al. Serum protein markers for early detection of ovarian cancer. Proc. Natl. Acad. Sci. U.S.A..May 2005; 102(21): 7677-7682.
  11. 11. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011; 121: 487-491.
  12. 12. Moore RG, Miller C, DiSilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011; 118(2):280-288.
  13. 13. ROMA™ (HE4 EIA + ARCHITECT CA 125 IITM) prescribing information. Fujirebio Diagnostics, Inc., 2011.
  14. 14. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. Aug 2004; 64(16): 5882-90.
  15. 15. Zhang Z, Chan DW Cancer proteomics: In Pursuit of “True”Biomarker Discovery. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2283-2286.
  16. 16. Song J, Daniel W, ”Cancer proteomics”. Clinical proteomics. 12/2006; (1542-6416), 2(3): 129.
  17. 17. Hellstrom I, Hellstrom KE SMRP and HE4 as Biomarkers for Ovarian Carcinoma When Used Alone and in Combination with CA125 and/or Each Other. Advances in Experimental Medicine and Biology. 2008;622:15-21.
  18. 18. Hellstrom I, Friedman E, Verch T, Yang Y, Korach J, Jaffar J et al. Antimesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev. 2008;17:1520-6.
  19. 19. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J et al. Validation of serum biomarkers for detection of early-stage ovarian cancer. Am J Obstet Gynecol. 2009; 200:639
  20. 20. Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L et al. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1127-1133.
  21. 21. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM et al. A Framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res. 2011; 4: 375-383.
  22. 22. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J et al. New tumor markers: CA125 beyound. Int J Gynecol Cancer. 2005; 15: 274-281.
  23. 23. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008; 108: 402-408.
DOI: https://doi.org/10.2478/rrlm-2013-0046 | Journal eISSN: 2284-5623 | Journal ISSN: 1841-6624 (formerly 2284-5623)
Language: English, Romanian
Page range: 465 - 472
Published on: Dec 31, 2013
Published by: Romanian Association of Laboratory Medicine
In partnership with: Paradigm Publishing Services

© 2013 Octavian Gabriel J. Olaru, Cătălina Monica C. Pena, published by Romanian Association of Laboratory Medicine
This work is licensed under the Creative Commons License.